Although both melatonin and RORγ are recognised as potential therapeutic agents for obesity and diabetes, the role of the melatonin-RORγ axis in adiposity and glucose metabolism has not yet been reported. The gene discussed is RORC; the disease is obesity due to melanocortin 4 receptor deficiency.